Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer

Equality Impact Assessment (Guidance development) (PDF 142 KB)

Register of interests (PDF 131 KB)

Final draft guidance

Final appraisal document (PDF 238 KB)

Committee papers (PDF 8.38 MB)

Public committee slides (PDF 1.55 MB)

Final stakeholder list (PDF 208 KB)

Equality impact assessment (Scoping) (PDF 125 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 161 KB)

Final scope (PDF 214 KB)

Draft scope and provisional stakeholder list comments table (post-referral) (PDF 222 KB)

Draft scope and provisional stakeholder list comments table (post-referral) (PDF 206 KB)

Draft scope post referral (PDF 310 KB)

Draft matrix post referral (PDF 339 KB)